CO4950569A1 - Combinaciones antivirales - Google Patents

Combinaciones antivirales

Info

Publication number
CO4950569A1
CO4950569A1 CO98027484A CO98027484A CO4950569A1 CO 4950569 A1 CO4950569 A1 CO 4950569A1 CO 98027484 A CO98027484 A CO 98027484A CO 98027484 A CO98027484 A CO 98027484A CO 4950569 A1 CO4950569 A1 CO 4950569A1
Authority
CO
Colombia
Prior art keywords
loviride
cyclopenten
nevirapine
purin
cyclopropylamino
Prior art date
Application number
CO98027484A
Other languages
English (en)
Spanish (es)
Inventor
Clair Martha Heider St
David Walter Barry
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4950569A1 publication Critical patent/CO4950569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO98027484A 1997-05-17 1998-05-15 Combinaciones antivirales CO4950569A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations

Publications (1)

Publication Number Publication Date
CO4950569A1 true CO4950569A1 (es) 2000-09-01

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98027484A CO4950569A1 (es) 1997-05-17 1998-05-15 Combinaciones antivirales

Country Status (12)

Country Link
EP (1) EP0979082A1 (fr)
JP (1) JP2001525839A (fr)
AR (1) AR012702A1 (fr)
AU (1) AU7912398A (fr)
BR (1) BR9809127A (fr)
CA (1) CA2289655A1 (fr)
CO (1) CO4950569A1 (fr)
HR (1) HRP980264A2 (fr)
MA (1) MA26496A1 (fr)
NO (1) NO995620L (fr)
PE (1) PE74799A1 (fr)
WO (1) WO1998052570A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
EP1332757B1 (fr) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Formulation de comprimé d' efavirenz
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
WO2013111147A1 (fr) * 2011-12-19 2013-08-01 Hetero Research Foundation Compositions à libération prolongée de névirapine
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
MA26496A1 (fr) 2004-12-20
WO1998052570A1 (fr) 1998-11-26
HRP980264A2 (en) 1999-02-28
BR9809127A (pt) 2000-08-01
AR012702A1 (es) 2000-11-08
EP0979082A1 (fr) 2000-02-16
PE74799A1 (es) 1999-08-13
CA2289655A1 (fr) 1998-11-26
JP2001525839A (ja) 2001-12-11
NO995620D0 (no) 1999-11-16
AU7912398A (en) 1998-12-11
NO995620L (no) 2000-01-14

Similar Documents

Publication Publication Date Title
CY1124601T1 (el) Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv
CO4950569A1 (es) Combinaciones antivirales
BRPI0408347A (pt) derivados de pirimidina
BR9916367A (pt) Novos compostos de bifenila e de análogos debifenila como antagonistas da integrina
YU3696A (sh) Poboljšana sinteza ciklopropilacetilena
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
SE9702772D0 (sv) Novel compounds
HN2002000300A (es) Nuevos derivados de piperazina
CY1110933T1 (el) 5,7-διαμινοπυραζολο[4,3-d]πυριμιδινες με ανασταλτικη της pde-5 δραστικοτητα
SV2002000342A (es) Inhibidor de la glucogeno fosforilasa ref. pc.10753/20151/bb
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
MX170401B (es) Copolimero de bloque metodo para fabricarlo, precursores de diamina del mismo y metodo para preparar las diaminas y productos finales que comprenden el copolimero de bloque
TR199801996A2 (xx) Pirazol t�revleri, �retimi ve ila� olarak kullan�m�
HN2002000317A (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
AR038426A1 (es) Composicion de liberacion colonica
GT200300231A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
CA2585557A1 (fr) Nouveaux composes pharmaceutiques
DE69613691D1 (de) Tumor protease aktivierte prodrogen von phosphor-senfgasanalogen
ATE423103T1 (de) Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
HUP0400345A2 (hu) Vírusellenes aktivitású foszfono-pirimidin-származékok
SE9802574D0 (sv) Novel compounds
SV1999000117A (es) Derivados de sulfonamida ref. x-12302
WO2005062979A3 (fr) Dosages immunologiques, haptenes, immunogenes et anticorps pour agents therapeutiques anti-vih
ES2188273T3 (es) Farmacos anticarcinogenos a base de antraquinona.